Global Blood Therapeutics, Inc. (GBT)
NASDAQ: GBT · IEX Real-Time Price · USD
31.79
+0.86 (2.78%)
At close: Jun 24, 2022 4:00 PM
31.95
+0.16 (0.50%)
After-hours:
Jun 24, 2022 6:28 PM EDT
Income Statement (Annual)
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Year | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|
|
Revenue
|
194.75 | 123.8 | 2.11 | 0 | 0 | 0 | 0 | 0 | 0 |
|
Revenue Growth (YoY)
|
57.31% | 5773.01% | - | - | - | - | - | - | - |
|
Cost of Revenue
|
3.32 | 1.99 | 0.05 | 0 | 0 | 0 | 0 | 0 | 0 |
|
Gross Profit
|
191.43 | 121.82 | 2.06 | 0 | 0 | 0 | 0 | 0 | 0 |
|
Selling, General & Admin
|
266.99 | 210.85 | 117.09 | 51.44 | 31.44 | 20.96 | 9.67 | 3.86 | 2.31 |
|
Research & Development
|
212.14 | 155.12 | 174.56 | 131.31 | 87.81 | 62.16 | 36.66 | 16.32 | 12.86 |
|
Other Operating Expenses
|
0 | 0 | 0 | 0 | 0 | 0 | 0.07 | 0.33 | 0.5 |
|
Operating Expenses
|
479.12 | 365.97 | 291.64 | 182.74 | 119.25 | 83.13 | 46.39 | 20.51 | 15.66 |
|
Operating Income
|
-287.69 | -244.16 | -289.58 | -182.74 | -119.25 | -83.13 | -46.39 | -20.51 | -15.66 |
|
Interest Expense / Income
|
15.47 | 9.81 | 0.89 | 0.35 | 0 | 0 | 0 | 0 | 0 |
|
Other Expense / Income
|
-0.54 | -6.41 | -23.72 | -8.9 | -2.22 | -0.66 | -0.03 | 3.26 | 2.45 |
|
Pretax Income
|
-302.61 | -247.55 | -266.76 | -174.19 | -117.02 | -82.47 | -46.36 | -23.77 | -18.12 |
|
Income Tax
|
0.48 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
Net Income
|
-303.09 | -247.55 | -266.77 | -174.19 | -117.02 | -82.47 | -46.36 | -23.77 | -18.12 |
|
Preferred Dividends
|
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.74 |
|
Net Income Common
|
-303.09 | -247.55 | -266.77 | -174.19 | -117.02 | -82.47 | -46.36 | -23.77 | -19.85 |
|
Shares Outstanding (Basic)
|
63 | 61 | 58 | 51 | 42 | 33 | 13 | 2 | 1 |
|
Shares Outstanding (Diluted)
|
63 | 61 | 58 | 51 | 42 | 33 | 13 | 2 | 1 |
|
Shares Change
|
2.66% | 5.17% | 14.02% | 20.86% | 27.45% | 159.30% | 665.07% | 36.06% | - |
|
EPS (Basic)
|
-4.81 | -4.04 | -4.57 | -3.41 | -2.76 | -2.48 | -3.95 | -14.20 | -16.14 |
|
EPS (Diluted)
|
-4.81 | -4.04 | -4.57 | -3.41 | -2.76 | -2.48 | -3.95 | -14.20 | -16.14 |
|
Free Cash Flow Per Share
|
-4.13 | -3.60 | -3.39 | -2.74 | -2.27 | -2.08 | -2.49 | -12.21 | -12.71 |
|
Gross Margin
|
98.30% | 98.40% | 97.72% | - | - | - | - | - | - |
|
Operating Margin
|
-147.72% | -197.21% | -13737.38% | - | - | - | - | - | - |
|
Profit Margin
|
-155.63% | -199.96% | -12654.93% | - | - | - | - | - | - |
|
Free Cash Flow Margin
|
-133.53% | -178.20% | -9384.82% | - | - | - | - | - | - |
|
Effective Tax Rate
|
-0.16% | 0.00% | -0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
|
EBITDA
|
-278.53 | -226.92 | -255.94 | -169.24 | -115.37 | -81.31 | -45.49 | -23.11 | -17.58 |
|
EBITDA Margin
|
-143.02% | -183.29% | -12141.18% | - | - | - | - | - | - |
|
Depreciation & Amortization
|
8.62 | 10.82 | 9.93 | 4.61 | 1.66 | 1.16 | 0.87 | 0.67 | 0.53 |
|
EBIT
|
-287.15 | -237.74 | -265.87 | -173.85 | -117.02 | -82.47 | -46.36 | -23.77 | -18.12 |
|
EBIT Margin
|
-147.44% | -192.03% | -12612.33% | - | - | - | - | - | - |
Source: Financials are provided by
Nasdaq Data Link
and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).